




The relative strengths and weaknesses of Kiniksa Pharmaceuticals International plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals International plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Kiniksa Pharmaceuticals International plc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 354%, being 104% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	313,750
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,554
Liabilities, Non-Current	0
Other Assets	1,859
Other Compr. Net Income	-4.0
Other Expenses	-214
Other Liabilities	144
Other Net Income	4,719
Other Revenues	0
Property and Equipment	6,356
Research and Development	86,597
Selling, General and Administrative Expense	21,563

Output Variable	Value in 1000 USD
Assets	321,965
Liabilities	42,698
Expenses	107,946
Revenues	0
Stockholders Equity	279,267
Net Income	-103,227
Comprehensive Net Income	-103,229
BaseVar	238,666
ECR before LimitedLiability	277%
Economic Capital Ratio	354%